Welcome introduction to @gecp_org 16th Congress lead by @MARIANOPROVENCI More than 500 attendees marking a new milestone in the group. 💪 Together against lung cancer 🫁 #LCSM #LCAM

16 Congress on Lung Cancer Barcelona 27- 28 Nov 2025. Very proud to have coordinated the program for this course together with @ECarcereny @bmassutis and @mprovencio. A great success with over 560 attendees!. @gecp_org #16CongressOnLungCancer @Hospital_FJD @UAM_Madrid #LCSM

Definition of a central vs ultra-central lung tumor #radonc #lcsm

Happiest Thanksgiving turkey and many positive trials, onc friends! #lcsm

DeLLphi-303: Tarlatamab 1L ES-SCLC 👉 Ph1b for safety ✅ ORR 71%, mPFS 10.3m ❗️V impressive 12m OS = 80% ❌ Marked Gr3/4 tox, mainly haem ❌ CRS in 59%, most in C1 🧐 1L SCLC Rx now changed Unprecedented OS Need longer F/U + Ph3 study (D-312) Watch this one #LCSM #ESMO25

Our final newsletter of 2025 lands on Monday. If you want to find out what this year really taught us and what it means for our #lungcancer work next year - now’s the time to sign up. Get it in your inbox 🔗 https://t.co/nKMTlf3jsW #LCSM

🫁 DeLLphi-303: tarlatamab + 1L CT-IO in ES-SCLC. @myESMO Promising efficacy 👉🏻 ORR 71%, mPFS 9 mo, 12-mo OS 81%. CRS events mostly low grade. Supports ongoing phase III DeLLphi-312 trial. #ESMO25 #CánCare #SCLC #lcsm #Tarlatamab

High prevalence of #smoking at the county level is linked to a higher-than-expected incidence of multiple primary #cancers. Published in @CEBP_AACR. https://t.co/xjsfc6yojX #lcsm #LungCancerAwarenessMonth

🫁 Sequential therapy for advanced/metastatic #EGFRm #NSCLC 🫁 🫁 I’ve compiled it into a table. (PFS & OS only) 🌟 After #ESMO25 🌟 OptiTROP-Lung04 (Sac-TMT) & Iza-bren (BL-B01D1) mono-therapy were added. ⚠️ For reference only ⚠️ #lungcancer #nsclc #egfr #LCSM

🆙 #ESMO25 🇩🇪 🔥#LCSM Proffered paper: Develop Tx ☑️Telisotuzumab adizutecan (ABBV-400; Temab-A) in patients with MET-amplified (MET-amp) advanced solid tumors: Results from a phase I study ☑️ORR in NSCLC 69％ 🎙️ Dr. Yonina R. Murciano-Goroff @OncoAlert @myESMO @Larvol

📣#OncTwitter #bcsm #lcsm RCT (N=98) in pts w/ leptomeningeal disease: Proton craniospinal radiation (pCSI) vs involved field radiotherapy (IFRT) 30Gy in 10 fractions Stopped at IA for superiority Final analysis 🏆 CNS-PFS: 8.2 vs 2.3m, p<.001 OS: 11.3 vs 4.9m Link ⬇️

Excellent presentation by Dr. Yasushi Yatabe from the National Cancer Center Singapore on #pathologic #response as both an #outcome and #predictor guiding #therapeutic #choices in early-stage #lungcancer. #HT25 @IASLC #LCSM @OncoAlert @oncodaily @lcsmchat @JSMO_official

Inspiring session with @Al3ssandroRusso brilliantly presenting old and new insights on ALK- and ROS1-positive #NSCLC being at the IV FONICAP–LILT National Congress @MinisteroSalute. 📊 Advancing clinical trials evidence meaningfully supports patient care. 🔬 #LCSM

Fantastic talk and data from @CelineMascaux presenting on immune evasion in early squamous cell carcinomas published in @Nature @IASLC #HT25 #LCSM

Week 3 of #LCAM & we’ve passed 1 million views! 💟 Grateful to everyone who’s shared their #lungcancer story & everyone taking the time to read, like & share to raise awareness that anyone can get lung cancer. Read all 56 stories here ➡️ https://t.co/yoltCYxL4t #LCSM

Selected from high impact abstracts, remarkable science shared by Dr. William Lockwood from BCCRC on Fine Particulate Matter PM2.5 as a Driver of Genomic Alterations and Lung Tumour Initiation. Truly impactful work. @IASLC #HT25 #LCSM @OncoAlert @oncodaily @lcsmchat

Rolf Stahel - such a well deserved winner of the @myESMO lifetime achievement award 🎉👏🎉 @etop_ibcsg #lcsm #ESMO25

We just learned for a fact that tarlatamab is indeed STARlatamab at the center of the small cell lung cancer Universe! @HemeOncBuddy #lcsm

OptiTROP-Lung04 ◽Sacituzumab Tirumotecan, an anti-TROP2 ADC, in 2L in EGFRmut NSCLC after PD to TKI ◽Without TROP2 biomarker analysis, 93% received 3rd Generation TKI ◽Positive study for PFS and OS with median not reached, with 40% risk reduction @OncoAlert #ESMO25 #lcsm